Alternative mechanisms of miR-34a regulation in cancer

被引:214
作者
Slabakova, Eva [1 ]
Culig, Zoran [2 ,3 ]
Remsik, Jan [1 ,2 ,4 ]
Soucek, Karel [1 ,2 ,4 ]
机构
[1] Czech Acad Sci, Dept Cytokinet, Inst Biophys, Brno, Czech Republic
[2] St Annes Univ Hosp Brno, Ctr Biomol & Cellular Engn, Int Clin Res Ctr, Brno, Czech Republic
[3] Med Univ Innsbruck, Div Expt Urol, Dept Urol, Innsbruck, Austria
[4] Masaryk Univ, Dept Expt Biol, Fac Sci, Brno, Czech Republic
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; MICRORNA BIOGENESIS; MOTILE CILIOGENESIS; MIRNA BIOGENESIS; PROSTATE-CANCER; FEEDBACK LOOP; CLL PATIENTS; MUTANT P53; STEM-CELLS;
D O I
10.1038/cddis.2017.495
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMTor inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.
引用
收藏
页码:e3100 / e3100
页数:10
相关论文
共 111 条
[1]   miR-34: from bench to bedside [J].
Agostini, Massimiliano ;
Knight, Richard A. .
ONCOTARGET, 2014, 5 (04) :872-881
[2]   Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets [J].
Agostini, Massimiliano ;
Tucci, Paola ;
Killick, Richard ;
Candi, Eleonora ;
Sayan, Berna S. ;
Cervo, Pia Rivetti di Val ;
Nicotera, Pierluigi ;
McKeon, Frank ;
Knight, Richard A. ;
Mak, Tak W. ;
Melino, Gerry .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (52) :21093-21098
[3]   ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression [J].
Ahn, Young-Ho ;
Gibbons, Don L. ;
Chakravarti, Deepavali ;
Creighton, Chad J. ;
Rizvi, Zain H. ;
Adams, Henry P. ;
Pertsemlidis, Alexander ;
Gregory, Philip A. ;
Wright, Josephine A. ;
Goodall, Gregory J. ;
Flores, Elsa R. ;
Kurie, Jonathan M. .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (09) :3170-3183
[4]  
[Anonymous], 2016, CANCER RES, V76, P3666
[5]   Transcriptional Repression of miR-34 Family Contributes to p63-Mediated Cell Cycle Progression in Epidermal Cells [J].
Antonini, Dario ;
Russo, Monia T. ;
De Rosa, Laura ;
Gorrese, Marisa ;
Del Vecchio, Luigi ;
Missero, Caterina .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (05) :1249-1257
[6]  
Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120
[7]   Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia [J].
Baer, Constance ;
Claus, Rainer ;
Frenzel, Lukas P. ;
Zucknick, Manuela ;
Park, Yoon Jung ;
Gu, Lei ;
Weichenhan, Dieter ;
Fischer, Martina ;
Pallasch, Christian Philipp ;
Herpel, Esther ;
Rehli, Michael ;
Byrd, John C. ;
Wendtner, Clemens-Martin ;
Plass, Christoph .
CANCER RESEARCH, 2012, 72 (15) :3775-3785
[8]   The quest for the 1p36 tumor suppressor [J].
Bagchi, Anindya ;
Mills, Alea A. .
CANCER RESEARCH, 2008, 68 (08) :2551-2556
[9]   Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors [J].
Beg, Muhammad S. ;
Brenner, Andrew J. ;
Sachdev, Jasgit ;
Borad, Mitesh ;
Kang, Yoon-Koo ;
Stoudemire, Jay ;
Smith, Susan ;
Bader, Andreas G. ;
Kim, Sinil ;
Hong, David S. .
INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) :180-188
[10]   p53-mediated activation of miRNA34 candidate tumor-suppressor genes [J].
Bommer, Guido T. ;
Gerin, Isabelle ;
Feng, Ying ;
Kaczorowski, Andrew J. ;
Kuick, Rork ;
Love, Robert E. ;
Zhai, Yali ;
Giordano, Thomas J. ;
Qin, Zhaohui S. ;
Moore, Bethany B. ;
MacDougald, Ormond A. ;
Cho, Kathleen R. ;
Fearon, Eric R. .
CURRENT BIOLOGY, 2007, 17 (15) :1298-1307